10-Q: Quarterly report pursuant to Section 13 or 15(d)
Published on August 6, 2024
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
________________________
FORM 10-Q
________________________
(Mark One)
For the quarterly period ended June 30, 2024
or
For the transition period from __________ to __________
Commission File Number
001-40860
________________________
(Exact name of registrant as specified in its charter)
________________________
|
|
|||||||
(State
or other jurisdiction of
incorporation
or organization)
|
(I.R.S.
Employer
Identification
No.)
|
(Address of principal executive offices and zip code)
(
310 ) 691-0776
(Registrant’s telephone number, including area code)
________________________
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
||||||||||||
|
|
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit such files).
Yes
☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated
filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the
Exchange Act.
Large Accelerated Filer | ☐ |
|
☒ | ||||||||
Non-accelerated Filer | ☐ | Smaller reporting company |
|
||||||||
Emerging growth company |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange
Act). Yes ☐ No
☒
As
of August 2, 2024, registrant had
661,984,685 shares of common stock, par value $0.001 per share, outstanding.
OLAPLEX HOLDINGS, INC.
TABLE OF CONTENTS
Page | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
1
GLOSSARY
As
used in this Quarterly Report on Form 10-Q (“Quarterly Report”), the terms identified below have the
meanings specified below unless otherwise noted or the context indicates otherwise. Except where the context
otherwise requires or where otherwise indicated, the terms “OLAPLEX”
“we,” “us,” “our,” “the Company,” and “our business” refer to Olaplex
Holdings, Inc.
and its consolidated subsidiaries.
•“2022
Credit Agreement”
refers to the Credit Agreement, dated as of February 23, 2022, by and among Olaplex, Inc., Penelope
Intermediate Corp, Goldman Sachs Bank USA, as administrative agent, collateral agent and swingline lender,
and each lender and issuing bank from time to time party thereto. The 2022 Credit Agreement includes, among
other things, a $675 million seven-year senior-secured term loan facility (the “2022 Term Loan Facility”)
and a $150 million five-year senior-secured revolving credit facility (the “2022 Revolver”).
•“IPO”
refers to the initial public offering of shares of common stock of Olaplex Holdings, Inc., completed on
October 4, 2021.
•“Penelope”
refers to Penelope Holdings Corp., which is an indirect parent of Olaplex, Inc., the Company’s primary
operating subsidiary.
•“Penelope
Group Holdings”
refers to Penelope Group Holdings L.P., which prior to the IPO was the direct parent of Penelope.
•“Pre-IPO
Stockholders”
refers to, collectively, (i) the former limited partners of Penelope Group Holdings prior to the
Reorganization Transactions and (ii) holders of options to purchase shares of common stock of Penelope that
were vested as of the consummation of the Reorganization Transactions.
•“Pre-IPO
Tax Assets”
refers to, collectively, certain tax attributes existing prior to the IPO, including tax basis in intangible
assets and capitalized transaction costs relating to taxable years ending on or before the date of the IPO
(calculated by assuming the taxable year of the relevant entity closes on the date of the IPO), that are
amortizable over a fixed period of time (including in tax periods beginning after the IPO) and which are
available to us and our wholly-owned subsidiaries.
•“Reorganization
Transactions”
refers to the internal reorganization completed in connection with our IPO, pursuant to which Olaplex
Holdings, Inc. became an indirect parent of Olaplex, Inc. For further information, see “Reorganization
Transactions” in “Note 1 - Nature of Operations and Basis of Presentation” to our Consolidated Financial
Statements included in Part II, Item 8 of our Annual Report on Form 10-K for the year ended December 31,
2023.
•“Tax
Receivable Agreement”
refers to the income tax receivable agreement entered into by the Company in connection with the
Reorganization Transactions under which the Company is required to pay the Pre-IPO Stockholders 85% of the
cash savings, if any, in United States (“U.S.”) federal, state or local tax that the Company actually
realizes on its taxable income following the IPO, as specified in the Tax Receivable Agreement.
2
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report contains certain forward-looking statements and information relating to us that are based
on the beliefs of our management as well as assumptions made by, and information currently available to, us.
These statements include, but are not limited to, statements about our strategies, plans, objectives,
expectations, intentions, expenditures and assumptions and other statements contained in or incorporated by
reference in this Quarterly Report that are not historical or current facts. When used in this document,
words such as “may,” “will,” “could,” “should,” “intend,” “potential,” “continue,” “anticipate,” “believe,”
“estimate,” “expect,” “plan,” “target,” “predict,” “project,” “forecast,” “seek” and similar expressions as
they relate to us are intended to identify forward-looking statements.
The
forward-looking statements in this Quarterly Report reflect our current expectations and projections about
future events and financial trends that we believe may affect our business, financial condition and results
of operation. Examples of forward-looking statements include, among others, statements we make regarding:
our financial position, sales and operating results; our business plans, strategies, investments and
objectives; general economic and industry trends; our business prospects; our reputation and brand; our
product technology; future product development and introduction; growth and expansion opportunities,
including expansion in existing markets and into new markets; our sales channels and omnichannel strategy;
legal proceedings; changes in laws and regulations; future payments under our Tax Receivable Agreement; our
customer base; our supply chain and global distribution network; our information technology; our employees
and culture; our operational capabilities; interest rate derivatives; and our expenses, inventory levels,
other working capital, indebtedness and liquidity. Forward-looking statements are predictions based upon
assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such,
you should not place significant reliance on our forward-looking statements. Neither we nor any other person
assumes responsibility for the accuracy and completeness of the forward-looking statements, including any
such statements taken from third party industry and market reports.
Forward-looking
statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to
predict which may cause our actual results, performance, time frames or achievements to be materially
different from any future results, performance, time frames or achievements expressed or implied by the
forward-looking statements, including, without limitation, the following:
•competition
in the beauty industry;
•our
ability to effectively maintain and promote a positive brand image, expand our brand awareness and maintain
consumer confidence in the quality, safety and efficacy of our products;
•our
ability to anticipate and respond to market trends and changes in consumer preferences and execute on our
growth strategies and expansion opportunities, including with respect to new product introductions;
•our
ability to accurately forecast customer and consumer demand for our products;
•our
dependence on the success of our long-term strategic plan;
•our
ability to limit the illegal distribution and sale by third parties of counterfeit versions of our products
or the unauthorized diversion by third parties of our products;
•our
dependence on a limited number of customers for a large portion of our net sales;
•our
ability to develop, manufacture and effectively and profitably market and sell future products;
•our
ability to attract new customers and consumers and encourage consumer spending across our product
portfolio;
•our
ability to successfully implement new or additional marketing efforts;
•our
relationships with and the performance of our suppliers, manufacturers, distributors and retailers and our
ability to manage our supply chain;
•impacts
on our business from political, regulatory, economic, trade and other risks associated with operating
internationally;
•our
ability to manage our executive leadership changes and to attract and retain senior management and other
qualified personnel;
•our
reliance on our and our third-party service providers’ information technology;
•our
ability to maintain the security of confidential information;
•our
ability to establish and maintain intellectual property protection for our products, as well as our ability
to operate our business without infringing, misappropriating or otherwise violating the intellectual
property rights of others;
3
•the
outcome of litigation and regulatory proceedings;
•the
impact of changes in federal, state and international laws, regulations and administrative policy;
•our
existing and any future indebtedness, including our ability to comply with affirmative and negative
covenants under the 2022 Credit Agreement;
•our
ability to service our existing indebtedness and obtain additional capital to finance operations and our
growth opportunities;
•volatility
of our stock price;
•our
“controlled company” status and the influence of investment funds affiliated with Advent International, L.P.
over us;
•the
impact of an economic downturn and inflationary pressures on our business;
•fluctuations
in our quarterly results of operations;
•changes
in our tax rates and our exposure to tax liability; and
•the
other factors identified in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended
December 31, 2023 (the “2023 Form 10-K”) and in other documents that we file with the U.S. Securities and
Exchange Commission from time to time.
Many
of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual
results, performance or achievements may vary materially from those described in this Quarterly Report as
anticipated, believed, estimated, expected, intended, planned or projected. We discuss many of these risks
in greater detail in the “Risk Factors” section of our 2023 Form 10-K. The forward-looking statements
included in this Quarterly Report are made only as of the date hereof. Unless required by law, we neither
intend nor assume any obligation to update these forward-looking statements for any reason after the date of
this Quarterly Report to conform these statements to actual results or to changes in our expectations or
otherwise.
4
PART
I - FINANCIAL INFORMATION
ITEM 1. Financial Statements
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts
in thousands, except per share and share data)
(Unaudited)
June 30, 2024 | December 31, 2023 | ||||||||||
Assets | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ |
|
$ |
|
|||||||
Accounts
receivable, net of allowances of $
|
|
|
|||||||||
Inventory |
|
|
|||||||||
Other current assets |
|
|
|||||||||
Total current assets |
|
|
|||||||||
Property and equipment, net |
|
|
|||||||||
Intangible assets, net |
|
|
|||||||||
Goodwill |
|
|
|||||||||
Other assets |
|
|
|||||||||
Total assets | $ |
|
$ |
|
|||||||
Liabilities and stockholders’ equity | |||||||||||
Current Liabilities: | |||||||||||
Accounts payable | $ |
|
$ |
|
|||||||
Sales and income taxes payable |
|
|
|||||||||
Accrued expenses and other current liabilities |
|
|
|||||||||
Current portion of long-term debt |
|
|
|||||||||
Current
portion of Related Party payable pursuant to Tax Receivable Agreement
|
|
|
|||||||||
Total current liabilities |
|
|
|||||||||
Long-term debt |
|
|
|||||||||
Deferred tax liabilities |
|
|
|||||||||
Related Party payable pursuant to Tax Receivable Agreement |
|
|
|||||||||
Other liabilities |
|
|
|||||||||
Total liabilities |
|
|
|||||||||
Contingencies
(Note 11)
|
|
|
|||||||||
Stockholders’
equity (Notes 1 and 9):
|
|||||||||||
Common
stock, $
|
|
|
|||||||||
Preferred
stock, $
|
|
|
|||||||||
Additional
paid-in capital
|
|
|
|||||||||
Accumulated other comprehensive income |
(
|
|
|||||||||
Retained
earnings
|
|
|
|||||||||
Total stockholders’ equity |
|
|
|||||||||
Total liabilities and stockholders’ equity | $ |
|
$ |
|
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
5
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(amounts
in thousands, except per share and share data)
(Unaudited)
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Cost of sales: | |||||||||||||||||||||||
Cost of product (excluding amortization) |
|
|
|
|
|||||||||||||||||||
Amortization of patented formulations |
|
|
|
|
|||||||||||||||||||
Total cost of sales |
|
|
|
|
|||||||||||||||||||
Gross profit |
|
|
|
|
|||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling, general, and administrative |
|
|
|
|
|||||||||||||||||||
Amortization of other intangible assets |
|
|
|
|
|||||||||||||||||||
Total operating expenses |
|
|
|
|
|||||||||||||||||||
Operating income |
|
|
|
|
|||||||||||||||||||
Interest expense |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Interest income |
|
|
|
|
|||||||||||||||||||
Other expense, net |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Income
before provision for income taxes
|
|
|
|
|
|||||||||||||||||||
Income tax provision |
|
|
|
|
|||||||||||||||||||
Net income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Net income per share: | |||||||||||||||||||||||
Basic | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Diluted | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||
Basic |
|
|
|
|
|||||||||||||||||||
Diluted |
|
|
|
|
|||||||||||||||||||
Other
comprehensive (loss) income:
|
|||||||||||||||||||||||
Unrealized
(loss) gain on derivatives, net of income tax effect
|
$ | (
|
$ |
|
$ | (
|
$ |
|
|||||||||||||||
Total
other comprehensive (loss) income
|
(
|
|
(
|
|
|||||||||||||||||||
Comprehensive income | $ |
|
$ |
|
$ |
|
$ |
|
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
6
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(amounts
in thousands, except number of shares)
(Unaudited)
Shares
|
Amount |
Additional
Paid in Capital |
Accumulated
Other Comprehensive Income (Loss)
|
Retained
Earnings |
Total Equity | ||||||||||||||||||||||||||||||
Balance - December 31, 2023 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Issuance of shares upon exercise of stock options and vesting of restricted stock units |
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized loss on derivatives (net of taxes) | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
Balance – March 31, 2024 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | $ | — | $ | — | $ | — | $ |
|
$ |
|
||||||||||||||||||||||||
Issuance of shares upon exercise of stock options and vesting of restricted stock units |
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized
loss on derivatives (net of taxes)
|
— | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
Balance
– June 30, 2024
|
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
||||||||||||||||||||||||
Shares
|
Amount |
Additional
Paid in Capital |
Accumulated Other Comprehensive Income |
Retained Earnings |
Total Equity | ||||||||||||||||||||||||||||||
Balance - December 31, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Issuance
of shares upon exercise of stock-settled stock appreciation rights
|
|
— |
|
— | — |
|
|||||||||||||||||||||||||||||
Shares withheld and retired on exercise of stock-settled stock appreciation rights |
(
|
— |
(
|
— | — |
(
|
|||||||||||||||||||||||||||||
Issuance
of shares upon exercise of stock options
|
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized loss on derivatives (net of taxes) | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
Balance – March 31, 2023 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Issuance
of shares upon exercise of stock options
|
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— |
|
||||||||||||||||||||||||||||||
Unrealized gain on derivatives (net of taxes) | — | — | — |
|
|
||||||||||||||||||||||||||||||
Balance – June 30, 2023 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
7
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts
in thousands)
(Unaudited)
Six Months Ended June 30, | |||||||||||
2024 | 2023 | ||||||||||
Cash
flows from operating activities:
|
|||||||||||
Net income | $ |
|
$ |
|
|||||||
Adjustments
to reconcile net income to net cash provided by operating activities:
|
|||||||||||
Amortization
of patent formulations
|
|
|
|||||||||
Amortization
of other intangibles
|
|
|
|||||||||
Inventory
write-off and disposal
|
|
|
|||||||||
Depreciation
of fixed assets
|
|
|
|||||||||
Amortization
of debt issuance costs
|
|
|
|||||||||
Deferred
taxes
|
(
|
|
|||||||||
Share-based
compensation expense
|
|
|
|||||||||
Other operating |
|
|
|||||||||
Changes in operating assets and liabilities: | |||||||||||
Accounts
receivable, net
|
|
(
|
|||||||||
Inventory
|
(
|
|
|||||||||
Other
current assets
|
(
|
(
|
|||||||||
Accounts
payable
|
|
|
|||||||||
Accrued
expenses, sales tax and income tax payable
|
(
|
|
|||||||||
Other assets and liabilities |
|
(
|
|||||||||
Net cash provided by operating activities |
|
|
|||||||||
Cash flows from investing activities: | |||||||||||
Purchase
of property and equipment
|
(
|
(
|
|||||||||
Purchase of intangible assets |
|
(
|
|||||||||
Purchase
of software
|
(
|
(
|
|||||||||
Net cash used in investing activities |
(
|
(
|
|||||||||
Cash flows from financing activities: | |||||||||||
Proceeds
from exercise of stock options
|
|
|
|||||||||
Payments
related to shares withheld and retired to cover tax withholding obligation for
SARs
|
|
(
|
|||||||||
Payment
to Pre-IPO Stockholders pursuant to Tax Receivable Agreement
|
(
|
(
|
|||||||||
Principal
payments for 2022 Term Loan Facility
|
(
|
(
|
|||||||||
Payments
for shares withheld and retired to cover tax withholding obligation for RSUs
|
(
|
|
|||||||||
Net cash used in financing activities |
(
|
(
|
|||||||||
Net increase in cash and cash equivalents |
|
|
|||||||||
Cash and cash equivalents - beginning of period |
|
|
|||||||||
Cash and cash equivalents - end of period | $ |
|
$ |
|
|||||||
Supplemental disclosure of cash flow information: | |||||||||||
Cash
paid for income taxes
|
$ |
|
$ |
|
|||||||
Cash
paid during the year for interest
|
$ |
|
$ |
|
|||||||
Supplemental disclosure of noncash activities: | |||||||||||
Assets acquired under operating lease | $ |
|
$ |
|
|||||||
Intangible assets non cash transaction | $ |
|
$ |
|
|||||||
Property and equipment non cash transaction | $ |
|
$ |
|
|||||||
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
8
OLAPLEX HOLDINGS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in
thousands, except share and per share amounts, percentages and as otherwise indicated)
(Unaudited)
NOTE 1- NATURE OF OPERATIONS AND BASIS OF PRESENTATION
Olaplex
Holdings, Inc. (“Olaplex Holdings” and, together with its subsidiaries, the “Company”) is a Delaware
corporation that was incorporated on June 8, 2021. Olaplex Holdings is organized as a holding company
and operates indirectly through Olaplex, Inc., its wholly owned indirect subsidiary, which conducts
business under the name “Olaplex”. Olaplex is an innovative, science-enabled, technology-driven beauty
company that is focused on delivering its patent-protected prestige hair care products to professional
hair salons, retailers and everyday consumers. Olaplex develops, manufactures and distributes a line of
hair care products developed to address three key uses: treatment, maintenance and protection.
Basis of Presentation
The
accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared in
accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial
information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by
the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the
information and footnotes required by U.S. GAAP for complete financial statements. The unaudited
interim Condensed Consolidated Financial Statements furnished reflect all adjustments which are, in
the opinion of management, necessary for a fair statement of the results for the interim periods
presented. The results of operations of any interim period are not necessarily indicative of the
results of operations to be expected for the full fiscal year. The unaudited interim Condensed
Consolidated Financial Statements should be read in conjunction with the Consolidated Financial
Statements and accompanying footnotes included in the Company’s 2023 Form 10-K.
NOTE 2 –
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Estimates and Assumptions
Preparing
financial statements requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenue, and expenses. Examples of estimates and assumptions
include: for revenue recognition, determining the nature and timing of satisfaction of performance
obligations, variable consideration, and other obligations such as product returns, allowance for
promotions, and refunds; loss contingencies; the fair value of share-based options and stock settled
stock appreciation rights (“SARs”); the fair value of and/or potential impairment of goodwill and
intangible assets for the Company’s reporting unit; the fair value of the Company’s Interest Rate
Caps (as defined below in “Note 5 - Fair Value Measurement”); useful lives of the Company’s tangible
and intangible assets; estimated income tax expense and tax payments; future payment obligations
under the Tax Receivable Agreement; and the net realizable value of, and demand for the Company’s
inventory. Actual results and outcomes may differ from management’s estimates and assumptions due to
risks and uncertainties.
Fair Value of Financial Instruments
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement date. The
authoritative guidance for fair value measurements established a framework for measuring fair value
and established a three-level valuation hierarchy for disclosure of fair value measurements as
follows:
Level 1—Observable
inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active
markets. The Company’s Level 1 assets consist of its marketable securities.
Level 2—Observable
quoted prices for similar assets or liabilities in active markets and observable quoted prices for
identical assets or liabilities in markets that are not active.
Level 3—Unobservable
inputs that are not corroborated by market data.
Cash
and cash equivalents, accounts receivable, accounts payable and accrued expenses are reflected at
carrying value, which approximates fair value due to the short-term maturity. The Company’s
long-term debt is recorded at its carrying
9
value
in the Condensed Consolidated Balance Sheets, which may differ from fair value. The Company’s
Interest Rate Caps are recorded at their Level 2 fair values in the Condensed Consolidated Balance
Sheets.
Accounting Policies
There
have been no material changes in significant accounting policies as described in the Company’s
Consolidated Financial Statements for the year ended December 31, 2023.
Constructive Retirement of Common Stock Repurchases
When
the Company's common stock is retired or purchased for constructive retirement for net share
settlement of stock options, any excess purchase price over par value is allocated between
additional paid-in-capital, to the extent that previous net gains from sales or retirements are
included therein, and the remainder to retained earnings.
Tax Receivable Agreement
In
connection with the Reorganization Transactions, the Company entered into the Tax Receivable
Agreement under which the Company will be required to pay to the Pre-IPO Stockholders
85 % of the federal, state or local tax cash savings that the Company actually
realizes on its taxable income following the IPO, as a result of the amortization of intangible
assets and capitalized transaction costs that existed as of the date of the IPO. Under the Tax
Receivable Agreement, generally the Company will retain the benefit of the remaining 15
% of the applicable tax savings.
The
Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that
the Company and its subsidiaries will earn sufficient taxable income to realize the full tax
benefits subject to the Tax Receivable Agreement. Updates to the Company’s blended state tax rate,
allocation of U.S. versus foreign sourced income and changes in tax rules on the amortization and
depreciation of assets may significantly impact the established liability, and changes to that
established liability would be recorded to other (expense) income in the period the Company made the
determination regarding the applicable change. The Company expects that future payments under the
Tax Receivable Agreement relating to the Pre-IPO Tax Assets could aggregate to $185.4 million
over
the 11-year remaining period under the Tax
Receivable Agreement. Payments under the Tax Receivable Agreement, which began in the year ended
December 31, 2022, are not conditioned upon the parties’ continued ownership of equity in the
Company.
Recent Accounting Pronouncements Not Yet Adopted
In
November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses.
The new guidance is effective for fiscal years beginning after December 15, 2023, and interim
periods within fiscal years beginning after December 15, 2024, and early adoption is permitted. The
guidance is to be applied retrospectively to all prior periods presented in the financial
statements. Upon transition, the segment expense categories and amounts disclosed in the prior
periods should be based on the significant segment expense categories identified and disclosed in
the period of adoption. The Company is currently evaluating the potential impact of adopting this
new guidance on its consolidated financial statements and related disclosures.
In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, “Income Taxes (Topic 740):
Improvements to Income Tax Disclosures, which modifies the rules on income tax disclosures to
require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or
loss from continuing operations before income tax expense or benefit (separated between domestic and
foreign) and (3) income tax expense or benefit from continuing operations (separated by federal,
state and foreign). This update also requires entities to disclose their income tax payments to
international, federal, state and local jurisdictions, among other changes. The new guidance is
effective for annual periods beginning after December 15, 2024. The Company is currently evaluating
the potential impact of adopting this new guidance on its consolidated financial statements and
related disclosures.
In
March 2024, the SEC adopted the final rule under SEC Release No. 33-11275, The Enhancement and
Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to
disclose certain climate-related information in annual reports. On April 4, 2024, the SEC determined
to voluntarily stay the final rules pending completion of a judicial review of certain legal
challenges. The Company is currently evaluating the final rule to determine its impact on the
Company's disclosures.
10
Reclassifications
Certain
amounts presented have been reclassified within the “Condensed Consolidated Statements of Operations
and Comprehensive Income” to conform with the current period presentation, including a prior year
reclassification from Interest expense, net to Interest income for the three and six months ended
June 30, 2023. The reclassifications occurred as a result of an increase in the significance of the
current year amount. There was no change to the Condensed Consolidated Balance Sheet, Statements of
Operations and Comprehensive Income, and Statements of Cash Flows from the reclassification.
NOTE 3 –
NET SALES
The
Company distributes products in the U.S. and internationally through professional distributors in
salons, directly to retailers for sale in their physical stores and e-commerce sites, and
direct-to-consumer (“DTC”) through sales to third-party e-commerce customers and through its own
Olaplex.com website.
As such, the Company’s three
business channels consist of professional, specialty retail and DTC as follows:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Net sales by Channel: | |||||||||||||||||||||||
Professional | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Specialty retail |
|
|
|
|
|||||||||||||||||||
DTC |
|
|
|
|
|||||||||||||||||||
Total net sales | $ |
|
$ |
|
$ |
|
$ |
|
Net
sales by major geographic region is based on the shipping address on record for the customer purchasing
the Company’s products. During the three and six
months ended June 30, 2024 and June 30, 2023, the Company’s net sales to consumers in the
United States and International regions were as follows:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Net sales by Geography: | |||||||||||||||||||||||
United States | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
International |
|
|
|
|
|||||||||||||||||||
Total net sales | $ |
|
$ |
|
$ |
|
$ |
|
For
the three and six months ended June 30, 2024, U.S. net sales included approximately $
2.4
million and $4.1
million, respectively, of net sales to customers with U.S. shipping addresses who the
Company expects will ultimately sell such products in international jurisdictions.
For
the three and six months ended June 30, 2023, U.S net sales included approximately $2.6
million and $4.8
million, respectively, of net sales to customers with U.S. shipping addresses who the
Company expects will ultimately sell such products in international jurisdictions.
No
international country exceeded 10% of total net sales for the three and six months ended June 30,
2024 and June 30, 2023. Despite our customers’ geographic location, the majority of net sales are
transacted in U.S. Dollars, the Company’s functional and reporting currency.
NOTE 4 - INVENTORY
Inventory
as of June 30, 2024 and December 31, 2023 consisted of the following:
June 30, 2024 | December 31, 2023 | ||||||||||
Raw materials | $ |
|
$ |
|
|||||||
Finished goods |
|
|
|||||||||
Inventory | $ |
|
$ |
|
11
During
the three and six months ended June 30, 2024, the Company recorded inventory write-offs of
$
1.6
million and $
2.5
million, respectively, due to reserves for product obsolescence.
During
the three and six months ended June 30, 2023, the Company recorded inventory write-offs of $
3.6 million and $6.2 million,
respectively, due to reserves for product obsolescence.
NOTE 5 – FAIR VALUE
MEASUREMENT
Fair
value measurements are established utilizing a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs that
reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2,
defined as observable quoted prices for similar assets or liabilities in active markets and observable
quoted prices for identical assets or liabilities in markets that are not active; and Level 3, defined
as unobservable inputs that are not corroborated by market data. The Company’s Level 1 assets consist of
its marketable securities. Financial assets and liabilities are classified in their entirety based on
the lowest level of input that is significant to the fair value measurement.
On
August 11, 2022, the Company entered into an interest rate cap transaction (the “2022 Interest Rate
Cap”) in connection with the 2022 Term Loan Facility, with a notional amount of $400 million. The 2022
Interest Rate Cap expired on July 31, 2024.
In
advance of the expiration of the 2022 Interest Rate Cap, on May 7, 2024, the Company entered into a
second interest rate cap transaction (the “2024 Interest Rate Cap” and, together with the 2022 Interest
Rate Cap, the “Interest Rate Caps”) in connection with the 2022 Term Loan Facility, with a notional
amount of $400
million. The 2024 Interest Rate Cap expires on July 31, 2026.
The
Interest Rate Caps were designated as cash flow hedges. For derivatives designated, and that qualify, as
cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated
other comprehensive income and subsequently reclassified into Interest expense in the same period(s)
during which the hedged transaction affects earnings, as documented at hedge inception in accordance
with the Company’s accounting policy election. The Interest Rate Caps assets are measured at fair value
on a recurring basis. Although the Company has determined that the majority of the inputs used to value
the Interest Rate Caps fall within Level 2 of the fair value hierarchy, the credit valuation adjustments
associated with the Interest Rate Caps utilize Level 3 inputs, such as estimates of current credit
spreads to evaluate the likelihood of default by the Company and its counterparties. The Company has
determined that the impact of the credit valuation adjustments made to the Interest Rate Caps were not
significant to the overall valuation. As a result, the Interest Rate Caps as of June 30, 2024 and
the 2022 Interest Rate Cap as of December 31, 2023 were classified as Level 2 of the fair value
hierarchy.
The
Company’s assets measured at fair value on a recurring basis and subject to fair value disclosure
requirements at June 30, 2024 and December 31, 2023 were as follows:
Fair Value Measurements at Reporting Date Using | ||||||||||||||||||||||||||
Total |
Quoted
Prices in Active Markets
for
Identical Assets
Level
1
|
Significant Other Observable Inputs Level 2 |
Significant Unobservable Inputs Level 3 |
|||||||||||||||||||||||
Assets: | ||||||||||||||||||||||||||
Current
Assets
|
||||||||||||||||||||||||||
2022
Interest Rate Cap at June 30, 2024
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
Other
Assets
|
||||||||||||||||||||||||||
2024
Interest Rate Cap at June 30, 2024
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
Other
Assets
|
||||||||||||||||||||||||||
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
12
NOTE 6 – GOODWILL AND INTANGIBLE ASSETS
Goodwill
and intangible assets are comprised of the following:
June 30, 2024 | |||||||||||||||||||||||
Estimated Useful Life |
Gross
Carrying Amount |
Accumulated
Amortization |
Net
Carrying
Amount
|
||||||||||||||||||||
Brand name |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||
Product formulations |
|
|
(
|
|
|||||||||||||||||||
Customer relationships |
|
|
(
|
|
|||||||||||||||||||
Software |
|
|
(
|
|
|||||||||||||||||||
Total
finite-lived intangibles
|
|
(
|
|
||||||||||||||||||||
Goodwill | Indefinite |
|
— |
|
|||||||||||||||||||
Total
goodwill and other intangibles
|
$ |
|
$ |
(
|
$ |
|
December 31, 2023 | |||||||||||||||||||||||
Estimated Useful Life |
Gross
Carrying Amount
|
Accumulated
Amortization |
Net
Carrying
Amount
|
||||||||||||||||||||
Brand name |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||
Product formulations |
|
|
(
|
|
|||||||||||||||||||
Customer relationships |
|
|
(
|
|
|||||||||||||||||||
Software |
|
|
(
|
|
|||||||||||||||||||
Total
finite-lived intangibles
|
|
(
|
|
||||||||||||||||||||
Goodwill | Indefinite |
|
— |
|
|||||||||||||||||||
Total
goodwill and other intangibles
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||
The
amortization of the Company’s brand name, customer relationships and software is recorded to
Amortization of other intangible assets in the Condensed Consolidated Statements of Operations and
Comprehensive Income. A portion of Amortization of patented formulations is capitalized to Inventory in
the Condensed Consolidated Balance Sheets, and the remainder is recorded to Amortization of patented
formulations in the Condensed Consolidated Statements of Operations and Comprehensive Income.
Amortization
of the Company’s definite-lived intangible assets for the three and six months ended June 30,
2024 and 2023 was as follows:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Amortization of patented formulations | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Amortization expense, brand name and customer relationships | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Amortization expense, software |
|
|
|
|
|||||||||||||||||||
Amortization
of other intangible assets
|
|
|
|
|
|||||||||||||||||||
Amortization of patented formulations capitalized to inventory | $ |
(
|
$ |
|
|
|
13
NOTE 7 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued
expenses as of June 30, 2024 and December 31, 2023 consisted of the following:
June 30, 2024 | December 31, 2023 | ||||||||||
Accrued professional fees | $ |
|
$ |
|
|||||||
Payroll liabilities |
|
|
|||||||||
Accrued freight |
|
|
|||||||||
Accrued advertising |
|
|
|||||||||
Deferred revenue |
|
|
|||||||||
Accrued interest |
|
|
|||||||||
Other accrued expenses and current liabilities |
|
|
|||||||||
Accrued expenses and other current liabilities | $ |
|
$ |
|
14
NOTE 8 - LONG-TERM DEBT
The
Company’s Long-Term Debt as of June 30, 2024 and December 31, 2023 consisted of the
following:
June 30, 2024 | December 31, 2023 | ||||||||||
Long-term debt | |||||||||||
Credit Agreement, dated as of February 23, 2022 (the “2022 Credit Agreement”) | |||||||||||
$
|
$ |
|
$ |
|
|||||||
$
|
|
|
|||||||||
Debt issuance costs |
(
|
(
|
|||||||||
Total
term loan debt
|
|
|
|||||||||
Less: Current portion |
(
|
(
|
|||||||||
Long-term
debt, net of debt issuance costs and current portion
|
$ |
|
$ |
|
(1)
As
of June 30, 2024 and December 31, 2023, the Company did not have outstanding amounts drawn
on the 2022 Revolver, including letters of credit and swingline loan sub-facilities. As of
June 30, 2024, the Company had $150 million of available borrowing capacity under the
2022 Revolver.
The
interest rate on outstanding debt under the 2022 Term Loan Facility was 8.9 % per annum as of June 30, 2024. The interest rates
for all facilities under the 2022 Credit Agreement are calculated based upon the Company’s election
among (a) an adjusted term secured overnight financing rate (“SOFR”) (subject to a 0.50
% floor with respect to the 2022 Term Loan Facility, and a 0 % floor with respect to the 2022 Revolver) plus an
additional interest rate spread, (b) with respect to a borrowing in Euros under the 2022 Revolver, a
euro interbank offered rate (subject to a 0
% floor) plus an additional interest rate spread, or (c) an “Alternate Base Rate” (as
defined in the 2022 Credit Agreement) (subject to a 1.50
% floor with respect to the 2022 Term Loan Facility, and a 1.00
% floor with respect to the 2022 Revolver) plus an additional interest rate spread.
Interest
expense, net of interest income and inclusive of debt amortization, for the three months ended
June 30, 2024 and June 30, 2023 was $
8.3 million
and $10.2 million, respectively, and for the six months ended
June 30, 2024 and June 30, 2023 was $
16.6 million
and $20.7 million, respectively.
The
fair value of the Company’s long-term debt is based on the market value of its long-term debt
instrument. Based on the inputs used to value the long-term debt, the Company’s long-term debt is
categorized within Level 2 in the fair value hierarchy. As of June 30, 2024, the carrying amount of
the Company’s long-term debt under the 2022 Credit Agreement was $653.1
million, and the fair value of the Company’s long-term debt was $633.4 million. As of December 31, 2023, the carrying amount of the
Company’s long-term debt under the 2022 Credit Agreement was $655.8 million, and the fair value of the Company’s long-term debt
was $615.1 million.
The
2022 Credit Agreement includes, among other things, customary negative and affirmative covenants
(including reporting, financial and maintenance covenants) and events of default (including a change of
control) for facilities of this type. In addition, the 2022 Credit Agreement includes a springing first
lien leverage ratio financial covenant, which is applicable only to the lenders under the 2022 Revolver.
The Company was in compliance with these affirmative and negative covenants on June 30, 2024 and
December 31, 2023. The 2022 Term Loan Facility and the 2022 Revolver are secured by substantially
all of the assets of Olaplex, Inc. and the other guarantors, subject to certain exceptions and
thresholds.
Interest Rate Cap Transactions
The
Company’s results are subject to risk from interest rate fluctuations on borrowings under the 2022
Credit Agreement, including the 2022 Term Loan Facility. The Company may, from time to time, utilize
interest rate derivatives in an effort to add stability to interest expense and to manage its exposure
to interest rate movements.
On
August 11, 2022, the Company entered into the 2022 Interest Rate Cap with a notional value of $
400.0 million in connection
with the 2022 Term Loan Facility. The 2022 Interest Rate Cap expired on July 31, 2024.
On
May 7, 2024, the Company entered into the 2024 Interest Rate Cap with a notional value of $
400.0 million (amortizing to
$200.0 million, commencing
August 29, 2025) in connection with the 2022 Term Loan Facility. The 2024 Interest Rate
15
Cap
expires on July 31, 2026. Fair value and the related classification of the Company’s Interest Rate Caps
are discussed in “Note 5 - Fair Value Measurement”.
During
the three and six months ended June 30, 2024, the Company’s Interest Rate Caps generated an
unrecognized pre-tax loss of $1.4
million and $1.9 million, respectively, recorded in accumulated other
comprehensive income on the Company’s Condensed Consolidated Balance Sheets. During the same periods,
the Company also recognized a $1.3 million and $2.7 million reduction,
respectively, in interest expense related to the Company’s receipt of funds as a result of an interest
rate cap settlement with the Company’s counterparty with respect to the 2022 Interest Rate Cap,
partially offset by $0.3
million and $0.6
million, respectively,
of
interest expense related to amortization of the interest rate cap premiums paid by the Company in
connection with the Interest Rate Caps.
During
the three and six months ended June 30, 2023, the Company’s 2022 Interest Rate Cap generated an
unrecognized pre-tax loss of $1.7
million and $1.0 million, respectively, recorded in accumulated other
comprehensive income on the Company’s Condensed Consolidated Balance Sheets. During the same periods,
the Company also recognized a $0.9 million and $1.5 million reduction,
respectively, in interest expense related the Company’s receipt of funds as a result of an interest rate
cap settlement with the Company’s counterparty, partially offset by $0.3 million and $0.5 million, respectively, related to amortization of the
interest rate cap premium paid by the Company in connection with the 2022 Interest Rate Cap.
The
Company performed an initial effectiveness assessment on the Interest Rate Caps and determined each to
be an effective hedge of the cash flows related to the interest rate payments
on the 2022 Term Loan Facility. The hedge is evaluated qualitatively on a quarterly basis for
effectiveness. Changes in fair value are recorded in accumulated other comprehensive income and periodic
settlements of the Interest Rate Caps will be recorded in interest expense along with the interest on
amounts outstanding under the 2022 Term Loan Facility. Payments of the up-front premiums of the Interest
Rate Caps are included within other current assets and other assets and liabilities within cash flows
from operating activities on the Company’s Condensed Consolidated Statements of Cash Flows.
The
Company does not hold or issue derivative financial instruments for trading purposes, nor does it hold
or issue leveraged derivative instruments. By using derivative financial instruments to hedge exposures
to interest rate fluctuations, the Company exposes itself to counterparty credit risk. The Company
manages exposure to counterparty credit risk by entering into derivative financial instruments with
highly rated institutions that can be expected to fully perform under the terms of the applicable
contracts.
NOTE 9 -
EQUITY
During
the six months ended June 30, 2024, the Company issued 1,098,285
shares
of its common stock, of which 297,945 shares were issued as a result of stock options
exercised and 800,340 shares were issued upon vesting of restricted stock
units.
During
the six months ended June 30, 2023, the Company issued 109,620 shares of its common
stock upon vesting and settlement of net stock-settled SARs. The Company withheld 83,501 of such shares of its common stock for the net
settlement payment of exercise price and taxes related to such SARs, which were accounted for as a share
retirement.
Additionally,
during the six months ended June 30, 2023, the Company issued 4,413,328 shares of its common
stock as a result of stock options exercised.
NOTE 10 - RELATED PARTY TRANSACTIONS
In
August 2023, the Company entered into an agreement with Pacvue Corporation, an e-commerce advertising
and software company, in which certain investment funds affiliated with Advent International L.P., the
holder of a majority of the Company’s common stock (collectively the “Advent Funds”), hold a greater
than 10% equity interest. During the three and six months ended June 30, 2024, the Company paid
Pacvue Corporation $91 thousand and $263 thousand, respectively.
No
payments were made to Pacvue Corporation during
the three and six months ended June 30, 2023.
In
connection with the Reorganization Transactions, the Company entered into the Tax Receivable Agreement
with the Pre-IPO Stockholders. See further discussion in “Note 2 – Summary of Significant Accounting
Policies – Tax Receivable Agreement”. During the three and six months ended June 30,
2024,
the Company made a payment of $
12.6
million, and during the three and six months ended June 30,
2023, the Company made a payment of $
16.6
million
to the Pre-IPO Stockholders, as
required pursuant to the terms of the Tax Receivable Agreement.
16
NOTE 11 - CONTINGENCIES
From
time to time, the Company is subject to various legal actions arising in the ordinary course of
business. The Company cannot predict with reasonable assurance the outcome of these legal actions
brought against the Company as they are subject to uncertainties. Accordingly, any settlement or
resolution in these legal actions may occur and affect the Company’s net income in such period as the
settlement or resolution.
Pending Legal Proceedings:
On
November 17, 2022, a putative securities class action was filed against the Company and certain of its
current and former officers and directors in the United States District Court for the Central District
of California, captioned Lilien
v. Olaplex Holdings, Inc. et al.,
No. 2:22-cv-08395. A consolidated complaint was filed on April 28, 2023, which names as additional
defendants the underwriters for the Company’s IPO and various stockholders that sold shares of common
stock of the Company in the IPO. The action is brought on behalf of a putative class of purchasers of
the Company’s common stock in or traceable to the Company’s IPO and asserts claims under Sections 11,
12, and 15 of the Securities Act of 1933. The action seeks certification of the putative class,
compensatory damages, attorneys’ fees and costs, and any other relief that the court determines is
appropriate. The defendants moved to dismiss the consolidated complaint on July 19, 2023. The court held
hearings on the defendants’ motions to dismiss on October 16, 2023 and July 1, 2024. A decision has yet
to be issued. The underwriter defendants have notified the Company of their intent to seek
indemnification from the Company pursuant to the IPO underwriting agreement regarding the claims
asserted in this action. The Company intends to vigorously defend the pending lawsuit.
On
November 15, 2023, a purported derivative action was filed against the Company, Advent International
Corporation, and certain of the Company’s current and former officers and directors in the United States
District Court for the Central District of California, captioned Ciuffo
v. Dagousset, et al.,
No. 2:23-cv-09712-SVW-SK. This action is premised on allegations similar to those asserted in the
Lilien
federal securities litigation. On February 1, 2024, the parties filed a joint stipulation to stay the
purported derivative action pending a decision on the motions to dismiss filed in the Lilien
federal
securities action.
On
March 22, 2024, a second purported derivative action was filed against the Company, Advent International
Corporation, and certain of the Company’s current and former officers and directors in the United States
District Court for the Central District of California, captioned Hutchinson
v. Advent International Corporation, et al.,
No. 2:24-cv-02364. This action is premised on allegations similar to those asserted in the Lilien
federal securities litigation and in the Ciuffo
federal derivative action. On April 19, 2024, the parties in both purported derivative actions filed a
joint stipulation to consolidate the two derivative actions and to stay proceedings in the consolidated
case.
On
February 9, 2023,
twenty-eight plaintiffs filed Albahae,
et al. v. Olaplex Holdings, Inc., et al.,
No. 2:23-cv-00982, a complaint alleging personal and economic injury and asserting claims for breach of
warranty, negligence/gross negligence, products liability, unjust enrichment, and violations of
California False Advertising Law and Unfair Competition Law, against the Company and Cosway Company,
Inc., the Company’s primary contract manufacturer, in the United States District Court for the Central
District of California. On March 2, 2023, the plaintiffs amended the complaint to include
seventy-three additional plaintiffs. The plaintiffs allege that certain ingredients
used in some Company products have purportedly caused irritation or posed a hazard to consumers, and
that the Company engaged in misrepresentation with respect to those products. The plaintiffs seek actual
and consequential damages, punitive damages, restitution in the form of disgorgement of profits,
attorneys’ fees and costs, and any other relief that the court determines is appropriate. On April 17,
2023, the Company moved to dismiss and to sever the plaintiffs’ claims. On July 11, 2023, the Court
granted the Company’s motion to sever and dismissed all but the first named plaintiff. The Court also
dismissed the operative complaint with leave to re-file on the grounds that it now contained allegations
that were not relevant to the claims of the one , remaining plaintiff. On July 24, 2023, the remaining
plaintiff filed a notice, voluntarily dismissing her claims without prejudice. As of the date of
issuance of these Condensed Consolidated Financial Statements, none of the plaintiffs have re-filed
their claims.
Any
potential loss associated with these pending legal proceedings
is not probable or reasonably estimable at this time.
As
of June 30, 2024 and December 31, 2023, the Company was not subject to any other currently
pending legal matters or claims that could have a material adverse effect on its financial position,
results of operations, or cash flows should such litigation be resolved unfavorably.
17
NOTE 12 – NET INCOME PER
SHARE
The
following is a reconciliation of the numerator and denominator in the basic and diluted net income
per common share computations:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Numerator: | |||||||||||||||||||||||
Net income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Denominator: | |||||||||||||||||||||||
Weighted
average common shares outstanding – basic
|
|
|
|
|
|||||||||||||||||||
Dilutive common equivalent shares from common stock equivalents |
|
|
|
|
|||||||||||||||||||
Weighted
average common shares outstanding – diluted
|
|
|
|
|
|||||||||||||||||||
Net income per share: | |||||||||||||||||||||||
Basic | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Diluted | $ |
|
$ |
|
$ |
|
$ |
|
Options
to purchase
10,269,710 and 9,578,809 shares of the Company’s
common stock for the three and six months ended June 30, 2024, respectively, and options to
purchase 2,965,541 and 1,459,061 shares of the Company’s
common stock for the three and six months ended June 30, 2023, respectively, were not included
in
the computation of diluted net income per share because the exercise prices of these options were
greater than the average market price per share of the Company’s common stock for the applicable period,
and therefore would have been anti-dilutive.
18
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
The
following discussion and analysis of our financial condition and results of operations should be read in
conjunction with our unaudited interim Condensed Consolidated Financial Statements and related notes
included elsewhere in this Quarterly Report and with our audited Consolidated Financial Statements included
in the 2023 Form 10-K.
Some
of the information contained in this discussion and analysis, including information with respect to our
plans and strategy for our business, includes forward-looking statements that involve risks and
uncertainties. Our actual results may differ materially from management’s expectations as a result of
various factors. Factors that could cause or contribute to these differences include, but are not limited
to, those identified below and those discussed in the section “Special Note Regarding Forward-Looking
Statements” in this Quarterly Report and in “Item 1A. - Risk Factors” in the 2023 Form 10-K.
Company Overview
OLAPLEX
is an innovative, science-enabled, technology-driven beauty company. Since our inception in 2014, we have
focused on delivering
effective, patent-protected and proven performance in the prestige hair care category.
OLAPLEX
disrupted and revolutionized the prestige hair care category by creating the bond-building space in 2014. We
have grown from an initial assortment of three products sold exclusively through the professional channel to
a broader suite of products offered through the professional, specialty retail and Direct to Consumer
(“DTC”) channels that have been strategically developed to address three key uses: treatment, maintenance
and protection. Our patent-protected bond-building technology relinks disulfide bonds in human hair that are
destroyed via chemical, thermal, mechanical, environmental and aging processes. Our current product
portfolio is comprised of nineteen unique and complementary products.
The
strength of our business model and ability to scale have created a compelling financial profile. We have
developed a synergistic omnichannel model that leverages the strength of each of our channels and our strong
digital capabilities that we apply across our sales platforms. Our professional channel serves as the
foundation for our brand. Through this channel, professional hairstylists introduce consumers to our
products and, we believe, influence consumer purchasing decisions. Our specialty retail channel works to
increase awareness of, and education for, our products and expand consumer penetration. Our DTC channel,
comprised of Olaplex.com and sales through third-party e-commerce platforms, also provides us with the
opportunity to engage directly with our consumers to provide powerful feedback that drives decisions we make
around new product development.
Strategic
Pillars
We
are focused on executing against our key strategic pillars that we believe will support our long-term
growth. These include igniting our global brand, disrupting with innovation, amplifying channel coverage and
charting new geographies. These key strategic pillars are supported by our efforts to build capabilities and
infrastructure that we believe will enable our aspirations.
Igniting our Global Brand
We
believe we have built one of the most powerful brands in the prestige hair care category. We plan to
continue growing awareness of our global brand, in an effort to deepen connections with existing customers
as well as reach new audiences. We will also continue to invest in enhancing our brand equity. Our marketing
model remains focused on implementing high return on investment, performance marketing activities aimed at
fueling growth. Key levers of our marketing include organic social media activations, strategic paid media,
education and training regarding our brand, community engagement with our professional hairstylists,
influencer partnerships, and retailer activations such as sampling and in-store events.
Disrupting with Innovation
We
believe we have a strong pipeline of disruptive innovation that leverages our science-based technology and
patented Bis-amino ingredient. We plan to launch two-to-four products annually over the next three years. To
support this pipeline, we intend to continue to invest in research and development to strengthen our
internal innovation capabilities. We recently entered into hair care adjacent categories and remain excited
about the opportunity to further grow where our technology can serve as a foundation for entry that we
believe is supported by consumer trust in our brand.
19
Amplifying Channel Coverage
In
our professional channel, we have undertaken efforts to support and reassert strong relationships with the
professional
hairstylist community and maintain brand awareness by increasing our field support efforts, deepening
partnerships with distributors and customers, and refreshing educational content. We are also pursuing
opportunities to further penetrate premium and prestige salons. In specialty retail, we are enhancing visual
merchandising in stores, investing in brand store pages online and deploying targeted communications
intended to enable new customer acquisition. For our DTC business, we are evolving the digital experiences
on Olaplex.com and third party e-commerce websites. On Olaplex.com, we expect to continue to invest in site
enhancements and more advanced personalization efforts.
Charting New Geographies
We
believe there is substantial opportunity to grow globally. Our priority international regions are currently
key markets in Europe and Asia. Across Europe and other regions, we aim to implement our business model by
first establishing a strong professional channel and then complementing that channel through entry into
specialty retail and DTC. In Asia, we intend to partner with distributors in the region that will support
omni-channel distribution and sales for our brand.
Supporting our Strategic Pillars
To
enable these key growth pillars, we intend to continue to build our capabilities and infrastructure. These
efforts extend across our organization, including focusing on cultivating top talent and building a strong
corporate culture, evolving our operational capabilities as we scale, creating a strong financial foundation
for growth, and ensuring that we have financial structure, technology and data to support our growth.
Business Environment & Trends
We
continue to monitor the effects of the global macro-economic environment, including the risk of recession,
inflationary pressures, competitive products and discounting, currency volatility, high interest rates,
social and political issues, geopolitical tensions and regulatory matters. We also are mindful of
inflationary pressures on our consumers, and are monitoring the impact that increasing inflationary
pressures may have on consumer spending and preferences and inventory rebalancing at our customers in an
increasingly competitive industry.
Competition
in the beauty industry is based on a variety of factors, including innovation, product efficacy, accessible
pricing, brand recognition and loyalty, service to the consumer, promotional activities, advertising,
special events, new product introductions, e-commerce initiatives, sustainability and other activities. We
have seen increased competitive activity including discounting in the prestige hair care category, which may
continue in a heightened inflationary environment. We believe we have a well-recognized and strong
reputation in our core markets and that the quality and performance of our products, our emphasis on
innovation, and our engagement with our professional and consumer communities position us to compete
effectively.
20
Second Quarter 2024 Financial Summary
•Net
sales decreased 4.8% from $109.2 million in the three months ended June 30, 2023 to $103.9 million in
the three months ended June 30, 2024. For the three months ended June 30, 2024, net sales in our
professional channel decreased 18.4%, our specialty retail channel increased 22.4% and our DTC channel
decreased 11.5%, in each case as compared to the three months ended June 30, 2023.
•Gross
profit margin decreased from 70.9% in the three months ended June 30, 2023 to 69.7% in the three months
ended June 30, 2024, primarily as a result of an expansion of our customer sampling program, product
and channel mix and increased promotional allowance, partially offset by decreases in warehouse and
distribution costs and a lower reserve for product obsolescence.
•Operating
expenses for the three months ended June 30, 2024 decreased by 4.4%, as compared to the three months
ended June 30, 2023, primarily as a result of lower professional fees, and lower non-payroll related
marketing and advertising expenses, partially offset by an increase in payroll costs due to workforce
expansion and merit increases, higher distribution and fulfillment costs and increased technology
investments in the three months ended June 30, 2024.
•Operating
income decreased from $18.8 million for the three months ended June 30, 2023 to $16.3 million for the
three months ended June 30, 2024.
•Net
income decreased from $6.2 million for the three months ended June 30, 2023 to $5.8 million for the
three months ended June 30, 2024.
Year to Date 2024 Financial Summary
•Net
sales decreased 9.0% from $223.0 million in the six months ended June 30, 2023 to $202.8 million in the
six months ended June 30, 2024. For the six months ended June 30, 2024, net sales in our
professional channel decreased 19.2%, our specialty retail channel increased 9.6% and our DTC channel
decreased 13.4%, in each case as compared to the six months ended June 30, 2023.
•Gross
profit margin decreased from 71.0% in the six months ended June 30, 2023 to 70.9% in the six months
ended June 30, 2024, primarily as a result of an expansion of our customer sampling program, product
and channel mix, increased promotional allowance and higher input costs for raw materials, partially offset
by decreases in warehouse and distribution costs and a lower reserve for product obsolescence.
•Operating
expenses for the six months ended June 30, 2024 increased by 3.8%, as compared to the six months ended
June 30, 2023, primarily as a result of an increase in payroll costs due to workforce expansion and
merit increases, higher distribution and fulfillment costs, higher employee benefit costs and increased
technology investments, partially offset by lower professional fees and lower non-payroll related marketing
and advertising expenses incurred in the six months ended June 30, 2024.
•Operating
income decreased from $54.3 million for the six months ended June 30, 2023 to $35.9 million for the six
months ended June 30, 2024.
•Net
income decreased from $27.1 million for the six months ended June 30, 2023 to $13.5 million for the six
months ended June 30, 2024.
21
Results of operations
Comparison of the Three Months Ended June 30, 2024 to the Three Months
Ended June 30, 2023
The
following table sets forth our Condensed Consolidated Statements of Operations and Comprehensive Income data
for each of the periods presented:
Three Months Ended June 30, | |||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||
(in thousands) | % of Net sales | (in thousands) | % of Net sales | ||||||||||||||||||||
Net sales | $ | 103,943 | 100.0 | % | $ | 109,241 | 100.0 | % | |||||||||||||||
Cost of sales: | |||||||||||||||||||||||
Cost of product (excluding amortization) | 29,204 | 28.1 | 29,781 | 27.3 | |||||||||||||||||||
Amortization of patented formulations | 2,302 | 2.2 | 1,964 | 1.8 | |||||||||||||||||||
Total cost of sales | 31,506 | 30.3 | 31,745 | 29.1 | |||||||||||||||||||
Gross profit | 72,437 | 69.7 | 77,496 | 70.9 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling, general, and administrative | 45,423 | 43.7 | 48,413 | 44.3 | |||||||||||||||||||
Amortization of other intangible assets | 10,736 | 10.3 | 10,324 | 9.5 | |||||||||||||||||||
Total operating expenses | 56,159 | 54.0 | 58,737 | 53.8 | |||||||||||||||||||
Operating income | 16,278 | 15.7 | 18,759 | 17.2 | |||||||||||||||||||
Interest expense | (14,594) | (14.0) | (14,674) | (13.4) | |||||||||||||||||||
Interest income | 6,259 | 6.0 | 4,468 | 4.1 | |||||||||||||||||||
Other
expense, net
|
(264) | (0.3) | (600) | (0.5) | |||||||||||||||||||
Income
before provision for income taxes
|
7,679 | 7.4 | 7,953 | 7.3 | |||||||||||||||||||
Income tax provision | 1,900 | 1.8 | 1,797 | 1.6 | |||||||||||||||||||
Net income | $ | 5,779 | 5.6 | $ | 6,156 | 5.6 | |||||||||||||||||
22
Net
Sales
We
distribute products in the U.S. and internationally through professional distributors in salons, directly to
retailers for sale in their physical stores and e-commerce sites, and DTC through sales to third party
e-commerce customers and through our Olaplex.com websites. As such, our three business channels consist of
professional, specialty retail and DTC as follows:
(in thousands) | Three Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 |
$
Change
|
%
Change
|
||||||||||||||||||||
Net sales by Channel: | |||||||||||||||||||||||
Professional | $ | 33,416 | $ | 40,940 | $ | (7,524) | (18.4) | % | |||||||||||||||
Specialty retail | 36,424 | 29,767 | 6,657 | 22.4 | % | ||||||||||||||||||
DTC | 34,103 | 38,534 | (4,431) | (11.5) | % | ||||||||||||||||||
Total Net sales | $ | 103,943 | $ | 109,241 | $ | (5,298) | (4.8) | % |
Total
net sales declined 4.8% in the three months ended June 30, 2024 compared to the same period in 2023,
primarily attributed to a lower level of demand. This decline was partially offset by our launch of
Browbond®
Building Serum and prior year launches of No. 5P Blonde Enhancer™ Toning Conditioner, Jumbo No. 4P Blonde
Enhancer™ Toning Shampoo and Jumbo No. 5P Blonde Enhancer™ Toning Conditioner, as well as the impact of new
customers within each channel. Net sales declined primarily in the United Kingdom and certain key markets in
continental Europe, partially offset by increases in the United States and Canada.
Cost
of Sales and Gross Profit
(in thousands) | Three Months Ended June 30, |
|
$ Change | % Change | |||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||
Cost of sales | $ | 31,506 | $ | 31,745 |
|
$ | (239) |
|
(0.8) | % | |||||||||||||
Gross profit | $ | 72,437 | $ | 77,496 |
|
$ | (5,059) |
|
(6.5) | % |
Our
cost of sales decreased primarily due to a decrease in product sales, decrease in warehouse and distribution
costs and a decrease in write-off for product obsolescence in the three months ended June 30, 2024. The
Company recorded $1.6 million in inventory write-offs during the three months ended June 30, 2024 as
compared to $3.6 million recorded during the three months ended June 30, 2023. The cost of sales
decline was partially offset by an expansion of our customer sampling program, as well as product mix and
channel mix in the three months ended June 30, 2024.
As
a result of the activity described above, our gross profit margin decreased from 70.9% in the three months
ended June 30, 2023 to 69.7% in the three months ended June 30, 2024.
Operating
Expenses
(in thousands) | Three Months Ended June 30, |
|
|||||||||||||||||||||
2024 | 2023 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Selling, general, and administrative expenses | $ | 45,423 | $ | 48,413 |
|
$ | (2,990) |
|
(6.2) | % | |||||||||||||
Amortization of other intangible assets | 10,736 | 10,324 |
|
412 |
|
4.0 | % | ||||||||||||||||
Total operating expenses | $ | 56,159 |
|
$ | 58,737 |
|
$ | (2,578) | (4.4) | % |
The
decrease in selling, general and administrative expenses was primarily driven by a decrease of
$5.7 million in professional fees and $3.3 million in non-payroll related marketing and
advertising expenses, partially offset by an increase of $3.8 million in payroll costs driven by
workforce expansion and merit increases, $0.9 million in distribution and fulfillment costs and
$0.8 million in technology investments incurred during the three months ended June 30,
2024.
23
Interest
Expense, Net
(in thousands) | Three Months Ended June 30, |
|
|
|
|||||||||||||||||||
2024 | 2023 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Interest expense | $ | (14,594) | $ | (14,674) | $ | 80 |
|
(0.5) | % | ||||||||||||||
Interest income | $ | 6,259 | $ | 4,468 | $ | 1,791 |
|
40.1 | % | ||||||||||||||
Interest expense, net | $ | (8,335) | $ | (10,206) | $ | 1,871 |
|
(18.3) | % |
Interest
income for the three months ended June 30, 2024 increased as compared to the previous year due to
additional investments in highly liquid investments with a maturity of three months or less.
Other
Expense, Net
(in thousands) | Three Months Ended June 30, |
|
|
|
|||||||||||||||||||
2024 | 2023 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Other
expense, net
|
$ | (264) | $ | (600) |
|
$ | 336 | (56.0) | % |
Other
expense, net decreased primarily due to foreign currency transactions losses driven by the performance of
the U.S. dollar.
Income
Tax Provision
(in thousands) | Three Months Ended June 30, |
|
|
|
|||||||||||||||||||
2024 | 2023 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Income tax provision | $ | 1,900 | $ | 1,797 | $ | 103 | 5.7 | % |
Our
effective tax rate increased to 24.7% for the three months ended June 30, 2024, as compared to 22.6%
for the three months ended June 30, 2023, primarily due to a shortfall associated with the vesting of
the restricted stock units.
Our
effective tax rate for the three months ended June 30, 2024 is higher than the statutory rate of 21%
primarily due to the effect of state income taxes and a discrete tax expense from restricted stock units
vested during the period, partially offset by the foreign derived intangible income (“FDII”) deduction,
which results in income from the Company’s sales to foreign customers being taxed at a lower effective tax
rate. Our effective tax rate in the three months ended June 30, 2023 was higher than the statutory tax
rate of 21% due to the effect of state income taxes, partially offset by the FDII deduction.
24
Results of operations
Comparison of the Six Months Ended June 30, 2024 to the Six Months Ended
June 30, 2023
The
following table sets forth our Condensed Consolidated Statements of Operations and Comprehensive Income data
for each of the periods presented:
Six Months Ended June 30, | |||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||
(in thousands) | % of Net sales | (in thousands) | % of Net sales | ||||||||||||||||||||
Net sales | $ | 202,849 | 100.0 | % | $ | 223,028 | 100.0 | % | |||||||||||||||
Cost of sales: | |||||||||||||||||||||||
Cost of product (excluding amortization) | 54,580 | 26.9 | 61,016 | 27.4 | |||||||||||||||||||
Amortization of patented formulations | 4,489 | 2.2 | 3,706 | 1.7 | |||||||||||||||||||
Total cost of sales | 59,069 | 29.1 | 64,722 | 29.0 | |||||||||||||||||||
Gross profit | 143,780 | 70.9 | 158,306 | 71.0 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling, general, and administrative | 85,860 | 42.3 | 83,337 | 37.4 | |||||||||||||||||||
Amortization of other intangible assets | 22,025 | 10.9 | 20,647 | 9.3 | |||||||||||||||||||
Total operating expenses | 107,885 | 53.2 | 103,984 | 46.6 | |||||||||||||||||||
Operating income | 35,895 | 17.7 | 54,322 | 24.4 | |||||||||||||||||||
Interest expense | (29,098) | (14.3) | (28,591) | (12.8) | |||||||||||||||||||
Interest income | 12,462 | 6.1 | 7,842 | 3.5 | |||||||||||||||||||
Other
expense, net
|
(1,211) | (0.6) | (358) | (0.2) | |||||||||||||||||||
Income
before provision for income taxes
|
18,048 | 8.9 | 33,215 | 14.9 | |||||||||||||||||||
Income tax provision | 4,523 | 2.2 | 6,095 | 2.7 | |||||||||||||||||||
Net income | $ | 13,525 | 6.7 | $ | 27,120 | 12.2 | |||||||||||||||||
Net
Sales
Net
sales by channel for the six months ended June 30, 2024 and June 30, 2023 were as follows:
(in thousands) | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 |
$
Change
|
%
Change
|
||||||||||||||||||||
Net sales by Channel: | |||||||||||||||||||||||
Professional | $ | 72,162 | $ | 89,337 | $ | (17,175) | (19.2) | % | |||||||||||||||
Specialty retail | 70,856 | 64,626 | 6,230 | 9.6 | % | ||||||||||||||||||
DTC | 59,831 | 69,065 | (9,234) | (13.4) | % | ||||||||||||||||||
Total Net sales | $ | 202,849 | $ | 223,028 | $ | (20,179) | (9.0) | % |
Total
net sales declined 9.0% in the six months ended June 30, 2024 compared to the same period in 2023, primarily
attributed to a lower level of demand. This decline was partially offset by our launch of
Browbond®
Building Serum and prior year launches of No. 5P Blonde Enhancer™ Toning Conditioner, Jumbo No. 4P Blonde
Enhancer™ Toning Shampoo and Jumbo No. 5P Blonde Enhancer™ Toning Conditioner, as well as the impact of new
customers within each channel. Net sales declined primarily in the United Kingdom and certain key markets in
continental Europe, partially offset by increases in the United States and in Latin America.
25
Cost
of Sales and Gross Profit
(in thousands) | Six Months Ended June 30, | $ Change | % Change | ||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||
Cost of sales | $ | 59,069 | $ | 64,722 |
|
$ | (5,653) |
|
(8.7) | % | |||||||||||||
Gross profit | $ | 143,780 | $ | 158,306 |
|
$ | (14,526) |
|
(9.2) | % |
Our
cost of sales decreased primarily due to a decrease in product sales, decrease in warehouse and distribution
costs and a decrease in write-off for product obsolescence in the six months ended June 30, 2024. The
Company recorded $2.5 million in inventory write-offs during the six months ended June 30, 2024 as
compared to $6.2 million recorded during the six months ended June 30, 2023. The cost of sales decline
was partially offset by an expansion of our customer sampling program, as well as product mix and channel
mix and higher input costs for raw materials in the six months ended June 30, 2024.
As
a result of the activity described above, our gross profit margin decreased from 71.0% in the six months
ended June 30, 2023 to 70.9% in the six months ended June 30, 2024.
Operating
Expenses
(in thousands) | Six Months Ended June 30, | ||||||||||||||||||||||
2024 | 2023 |
$
Change
|
%
Change
|
||||||||||||||||||||
Selling, general, and administrative expenses | $ | 85,860 | $ | 83,337 |
|
$ | 2,523 |
|
3.0 | % | |||||||||||||
Amortization of other intangible assets | 22,025 | 20,647 |
|
1,378 |
|
6.7 | % | ||||||||||||||||
Total operating expenses | $ | 107,885 |
|
$ | 103,984 |
|
$ | 3,901 | 3.8 | % |
The
increase in selling, general and administrative expenses was primarily driven by an increase of
$5.8 million in payroll costs driven by workforce expansion and merit increases, $2.1 million in
distribution and fulfillment costs, $1.3 million in technology investments, and $1.3 million of
employee benefit costs, partially offset by a decrease of $6.2 million in professional fees and $2.4
million of non-payroll related marketing and advertising expenses during the six months ended June 30,
2024.
Interest
Expense, Net
(in thousands) | Six Months Ended June 30, |
|
|
||||||||||||||||||||
2024 | 2023 |
$
Change
|
%
Change
|
||||||||||||||||||||
Interest expense | $ | (29,098) | $ | (28,591) | $ | (507) |
|
1.8 | % | ||||||||||||||
Interest income | $ | 12,462 | $ | 7,842 | $ | 4,620 |
|
58.9 | % | ||||||||||||||
Interest expense, net | $ | (16,636) | $ | (20,749) | $ | 4,113 |
|
(19.8) | % |
Interest
expense for the six months ended June 30, 2024 increased as compared to the previous year due to an increase
in interest rates, which was partially offset by benefits from the 2022 Interest Rate Cap. See “Liquidity
and Capital Resources Requirements – 2022 Credit Facility” for additional information on our outstanding
debt.
Interest
income for the six months ended June 30, 2024 increased as compared to the previous year due to increasing
interest rates and additional investments in highly liquid investments with a maturity of three months or
less.
Other
Expense, Net
(in thousands) | Six Months Ended June 30, |
|
|
||||||||||||||||||||
2024 | 2023 |
$
Change
|
%
Change
|
||||||||||||||||||||
Other
expense, net
|
$ | (1,211) | $ | (358) |
|
$ | (853) | 238.3 | % |
Other
expense, net increased primarily due to foreign currency transaction losses driven by the performance of the
U.S. dollar.
26
Income
Tax Provision
(in thousands) | Six Months Ended June 30, |
|
|
||||||||||||||||||||
2024 | 2023 |
$
Change
|
%
Change
|
||||||||||||||||||||
Income tax provision | $ | 4,523 | $ | 6,095 | $ | (1,572) | (25.8) | % |
Our
effective tax
rate increased to 25.1% for the six months ended June 30, 2024, as compared to 18.4% for the six months
ended June 30, 2023. The increase in the effective tax rate for the six months ended June 30, 2024 is
primarily due to the impact of a discrete tax expense for interest associated with income taxes and a
shortfall associated with the vesting of the restricted stock units during the period, compared to a
discrete tax benefit from stock option exercises during the six months ended June 30, 2023.
Our
effective tax rate for the six months ended June 30, 2024 was higher than the statutory rate of 21%
primarily due to the impact of the discrete tax expense for interest associated with income taxes, the
effect of state income taxes and a discrete tax expense from restricted stock units vested during the
period, partially offset by the FDII deduction. Our effective tax rate for the six months ended June 30,
2023 was lower than the statutory tax rate of 21% primarily due to the benefit associated with the FDII
deduction, as well as a discrete tax benefit from stock option exercises. These benefits were partially
offset by the net impact of state income taxes.
Financial Condition, Liquidity and Capital Resources
Overview
Our
primary recurring source of cash is the collection of proceeds from the sale of our products to our
customers, including cash periodically collected in advance of delivery or performance.
Our
primary use of cash is for working capital and payment of our operating costs, which consist primarily of
employee-related expenses as well as general operating expenses for marketing, fulfillment costs of customer
orders, overhead costs, innovation, capital expenditures and debt servicing. We also utilize cash for
strategic investments. Fluctuations in working capital are primarily caused by customer demand of our
product, timing of when a retailer rearranges or restocks our products, timing of inventory purchases, and
timing of our payables and expenses. Capital expenditures typically vary and are currently limited, and
future capital expenditure requirements depend on strategic initiatives selected for the fiscal year,
including investments in infrastructure, expansion into new national and international distributors and
expansion of our customer base.
A
considerable portion of our operating income is related to sales to customers outside
of the U.S.; however, the majority of our bank deposits are held within the U.S.
As
of June 30, 2024, we had $507.9 million of cash and cash equivalents. In addition, as of June 30,
2024, we had borrowing capacity of $150.0 million under the 2022 Revolver, plus $75.9 million of
working
capital excluding cash and cash equivalents for a combined liquidity position of $733.8 million.
27
Cash Flows
The
following table summarizes our cash flows for the periods presented:
Six Months Ended June 30, | |||||||||||
(in thousands) | 2024 | 2023 | |||||||||
Net cash provided by (used in): | |||||||||||
Operating activities | $ | 59,949 | $ | 75,087 | |||||||
Investing activities | (2,178) | (1,996) | |||||||||
Financing activities | (16,246) | (17,481) | |||||||||
Net increase in cash and cash equivalents: | $ | 41,525 | $ | 55,610 |
Operating Activities
The
change in net cash provided by operating activities during the six months ended June 30,
2024 compared to the same period in 2023
was primarily a result of a decrease in net income of $13.6 million, lower inventory write-offs and disposal
adjustments, as well as decreased deferred taxes, partially offset by increased share based compensation
expense, as well as higher amortization of intangible assets.
Investing Activities
Our
investing activities included purchases of software and property and equipment during the six months ended
June 30,
2024. Our
investing activities included purchases of software, intangibles and property and equipment during the six
months ended
June 30,
2023.
Financing Activities
Our
financing activities for the six months ended June 30,
2024 primarily consisted of cash outflows for payments on our long-term debt and debt issuance costs,
payments to our Pre-IPO Stockholders pursuant to our Tax Receivable Agreement, and
payments related to shares withheld and retired to cover the tax withholding obligations for vested
restricted stock units, partially offset by cash received by the Company from stock option exercises. For
the six months ended June 30, 2023, our financing activities primarily consisted of cash outflows for
payments on our long-term debt and debt issuance costs, payments to our Pre-IPO Stockholders pursuant to our
Tax Receivable Agreement, and payments related to shares withheld and retired to cover the tax withholding
obligations and exercise price for SARs, partially offset by cash received by the Company from stock option
exercises.
Liquidity and Capital Resources Requirements
Based
on past performance and current expectations, we believe that our cash, cash equivalents and cash generated
from operations will be sufficient to meet anticipated operating costs, required payments of principal and
interest, working capital needs, ordinary course capital expenditures, and other commitments
for at least the next 12 months.
If
necessary, we may borrow funds under our 2022 Revolver to finance our liquidity requirements, subject to
customary borrowing conditions. To the extent additional funds are necessary to meet our long-term liquidity
needs as we continue to execute our business strategy, we anticipate that they will be obtained through the
incurrence of additional indebtedness, equity financings or a combination of these potential sources of
funds; however, such financing may not be available on favorable terms, or at all. Our ability to meet our
operating, investing and financing needs depends, to a significant extent, on our future financial
performance, which will be subject in part to general economic, competitive, financial, regulatory and other
factors that are beyond our control, including those
described in “Item 1A. - Risk Factors” in our 2023
Form
10-K. In addition to these general economic and industry factors, the principal factors in determining
whether our cash flows will be sufficient to meet our liquidity requirements will be our ability to continue
providing innovative products to our customers and consumers and manage production and our supply
chain.
2022 Credit Facility
As
of June 30, 2024, we had outstanding indebtedness under the 2022 Credit Agreement of $659.8
million,
of which
$6.8 million was classified as current. As of June 30, 2024, we had $150.0 million of available
borrowing capacity under
the 2022
Revolver.
28
The
interest rate on outstanding amounts under the 2022 Term Loan Facility was 8.9% per annum as of
June 30, 2024. We have not drawn on the 2022 Revolver as of June 30, 2024. The 2022 Term Loan
Facility is repayable in mandatory quarterly installments equal to $1.6 million, with the balance payable at
maturity. The maturity date of the 2022 Term Loan Facility is February 23, 2029, and the maturity date of
the 2022 Revolver is February 23, 2027.
The
2022 Credit Agreement contains a number of covenants that, among other things, restrict the Company’s
ability to (subject to certain exceptions) pay dividends and distributions or repurchase its capital stock,
incur additional indebtedness, create liens on assets, engage in mergers or consolidations and sell or
otherwise dispose of assets. The 2022 Credit Agreement also includes reporting, financial and maintenance
covenants, including a springing first lien leverage ratio financial covenant. The Company was in compliance
with these affirmative and negative covenants on June 30, 2024 and December 31, 2023.
Substantially all the assets of the Company constitute collateral under the 2022 Credit Agreement.
On
August 11, 2022, we entered into an interest rate cap transaction (the “2022 Interest Rate Cap”) in
connection with the 2022 Term Loan Facility, with a notional amount of $400.0 million, in order to limit our
exposure to potential increases in future interest rates related to the 2022 Term Loan Facility. The 2022
Interest Rate Cap expired on July 31, 2024.
On
May 7, 2024, in advance of the expiration of the 2022 Interest Rate Cap, we entered into a second interest
rate cap transaction (the “2024 Interest Rate Cap” and, together with the 2022 Interest Rate Cap, the
“Interest Rate Caps”) in connection with the 2022 Term Loan Facility, with a notional amount of $400.0
million, amortizing to $200.0 million on August 29, 2025. The 2024 Interest Rate Cap expires on July 31,
2026. We have designated the Interest Rate Caps as cash-flow hedges for accounting purposes.
See
“Note 8
- Long-Term
Debt” in the Notes to the Condensed Consolidated Financial Statements included in Item 1. Financial
Statements of this Quarterly Report for additional
information.
Tax Receivable Agreement Obligations
In
connection with the Reorganization Transactions, we entered into the Tax Receivable Agreement under which we
will be required to pay to the Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that
we actually realize on our taxable income following the IPO, as a result of the amortization of intangible
assets and capitalized transaction costs that existed as of the transaction date. Under the Tax Receivable
Agreement, generally we will retain the benefit of the remaining 15% of the applicable tax savings.
The
Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that we and
our subsidiaries will earn sufficient taxable income to realize the full tax benefits subject to the Tax
Receivable Agreement. Updates to our blended state tax rate, allocation of U.S. versus foreign sourced
income and changes in tax rules on the amortization and depreciation of assets may significantly impact the
established liability and changes would be recorded to other (expense) income in the period we made the
determination. We expect that future payments under the Tax Receivable Agreement relating to the Pre-IPO Tax
Assets
could aggregate to $185.4 million over the 11-year remaining period under the Tax Receivable Agreement.
Payments under the Tax Receivable Agreement, which began in the year ended December 31, 2022, are not
conditioned upon the parties’ continued ownership of equity in the Company.
Contractual Obligations and Commitments
There
were no material changes to our contractual obligations since the filing of our 2023
Form 10-K.
Critical Accounting Policies and Estimates
Our
unaudited interim Condensed Consolidated Financial Statements have been prepared in accordance with U.S.
GAAP, which requires us to make estimates and assumptions that affect reported amounts. The estimates and
assumptions are based on historical experience and on other factors that we believe to be reasonable. Actual
results may differ from those estimates. We review these estimates on a periodic basis to ensure
reasonableness. Although actual amounts may differ from such estimated amounts, we believe such differences
are not likely to be material. For additional detail regarding our critical accounting policies including
revenue recognition, inventory, and the Tax Receivable Agreement, see our discussion for the year ended
December 31, 2023
in the 2023 Form 10-K.
There have been no material changes to these policies in the six months ended June 30, 2024.
29
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We
are exposed to certain market risks arising from transactions in the normal course of our business. This
includes risk associated with interest rates, our interest rate cap transactions, inflation and foreign
exchange.
Interest Rate Risk
Our
results are subject to risk from interest rate fluctuations on borrowings under the 2022 Credit Agreement.
Our borrowings bear interest at a variable rate; therefore, we are exposed to market risks relating to
changes in interest rates. Interest rate changes generally affect the amount of our interest payments and,
therefore, our future earnings and cash flows. As of
June 30, 2024,
we had
$659.8 million
of outstanding variable rate loans under the 2022 Term Loan Facility. Based on our June 30, 2024
variable rate loan
balances, an increase or decrease of 1% in the effective interest rate would cause an increase or decrease
in interest cost of approximately
$6.6 million
over the next 12 months.
Interest Rate Caps
On
August 11, 2022 and on May 7, 2024, we entered into the Interest Rate Caps in connection with the 2022 Term
Loan Facility, as more fully described in “Note 8 - Long-Term Debt” in the Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1. Financial Statements of this Quarterly Report.
We use the Interest Rate Caps to add stability to interest expense and to manage our exposure to interest
rate movements. The fair value of the Interest Rate Caps is measured at the end of each reporting period
using observable inputs other than quoted prices. The fair value of the Interest Rate Caps recorded in other
current assets and other assets at June 30, 2024 was $0.4 million and $1.2 million, respectively. A
hypothetical 50 basis point increase in interest rates would result in an increase to the fair value of the
Interest Rate Caps of approximately $1.5 million. A hypothetical 50 basis point decrease in interest
rates would result in a decrease to the fair value of the Interest Rate Caps of approximately
$0.8 million.
Inflation
Inflationary
factors such as increases in the cost to produce our products and overhead costs have adversely affected,
and may continue to adversely affect,
our operating results. Sustained increases in warehousing costs, transportation costs, wages and raw
material costs, or other inflationary pressures in the future, may have an adverse effect on our ability to
maintain current levels of gross profit margin if the selling prices of our products do not increase with
these increased costs, or if we cannot identify other cost efficiencies.
Foreign Exchange Risk
Our
reporting currency, including our U.K. foreign subsidiary, Olaplex UK Limited, is the U.S. dollar. Gains or
losses due to transactions in foreign currencies are reflected in the Condensed Consolidated Statements of
Operations and Comprehensive Income under the line-item Other (expense) income, net. We have not engaged in
the hedging of foreign currency transactions to date, although we may choose to do so in the future. We do
not believe that an immediate 10% increase or decrease in the relative value of the U.S. dollar to other
currencies would have a material effect on our condensed
consolidated financial statements.
30
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)) are designed to ensure that information required to
be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed,
summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that
information required to be disclosed is accumulated and communicated to our management, including our Chief
Executive Officer and Interim Chief Financial Officer, as appropriate, to allow for timely decisions
regarding required disclosures. In designing and evaluating the disclosure controls and procedures,
management recognizes that any controls and procedures, no matter how well-designed and operated, can
provide only reasonable assurance of achieving the desired control objectives.
Our
management has evaluated, under the supervision and with the participation of our Chief Executive Officer
and Interim Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this
Quarterly Report. Based on that evaluation, our Chief Executive Officer and Interim Chief Financial Officer
have concluded that our disclosure controls and procedures were effective as of June 30, 2024.
Changes in Internal Control Over Financial Reporting
There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f)
of the Exchange Act) that occurred during the quarter ended June 30, 2024 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
31
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We
have, and may in the future, from time to time, become involved in litigation or other legal proceedings
incidental to our business, including litigation related to intellectual property, regulatory matters,
contract, advertising and other consumer claims. In addition, we believe that protecting our intellectual
property is essential to our business and we have in the past, and may in the future, become involved in
proceedings to enforce our rights. Regardless of outcome, litigation (including the litigation referenced
below) can have an adverse impact on our reputation, financial condition and business, including by
utilizing our resources and potentially diverting the attention of our management from the operation of our
business.
For
detail on certain legal proceedings, see “Note 11
- Contingencies - Pending Legal Proceedings” included in the Notes to the Condensed Consolidated Financial
Statements included in Part I, Item 1. Financial Statements of this Quarterly Report.
ITEM 1A. RISK FACTORS
An
investment
in our common stock involves risks. For a detailed discussion of the risks that affect our business please
refer to “Item 1A. – Risk Factors” in the 2023
Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not
applicable.
ITEM 5. OTHER INFORMATION
(c)During
the three months ended June 30,
2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company
adopted
or
terminated
a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term
is defined in Item 408(a) of Regulation S-K.
32
ITEM 6. EXHIBITS
Exhibit Number | Description | |||||||
101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | |||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
#
Indicates a management contract or compensation plan, contract or arrangement.
†
This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise
subject to the liability of that section. Such certification will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
extent specifically incorporated by reference into such filing.
33
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this
report to be signed on its behalf by the undersigned thereunto duly authorized.
OLAPLEX HOLDINGS, INC. | |||||||||||
By: | /s/ Amanda Baldwin | ||||||||||
August 6, 2024 | Name: | Amanda Baldwin | |||||||||
Title: | Chief Executive Officer | ||||||||||
(Principal Executive Officer) | |||||||||||
By: |
/s/
Paul Kosturos
|
||||||||||
August 6, 2024 | Name: |
Paul
Kosturos
|
|||||||||
Title: |
Interim
Chief Financial Officer
|
||||||||||
(Principal
Financial Officer)
|
34